Novartis (NVS) stock slips as the company's anti-inflammatory agent Cosentyx fails primary goal in a Phase 3 trial for giant cell arteritis. Read more here/ ...

We came across a bullish thesis on Novartis AG (NVS) on Stock Analysis Compilation’s Substack. In this article, we will summarize the bulls’ thesis on NVS.

The U.S. Food and Drug Administration (FDA) announced new Q&A draft guidance on the “Transfer of a Premarket Notification (510 (k)) Clearance,” which provides information on the most ...

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Novartis (NVS) have what it takes? Let's find out.

NVS Quantitative Stock Analysis May 24, 2025 — 03:07 pm EDT Written by John Reese for Validea -> Below is Validea's guru fundamental report for NOVARTIS AG (ADR) (NVS).

NVS Non Teaching Exam Admit Card 2025 is now available for download at navodaya.gov.in. The exam is scheduled to start from May 15, 2025. Check here direct download link and steps to download ...

On a recent episode of Hard Knock Radio, host Davey D sat down with longtime homeless advocate and cultural organizer Needa Bee to revisit the origins, intentions, and future of 510 Day, a grassroots ...

NVS-02 is a second-generation navigation satellite of the Indian regional navigation satellite system NavIC. It was launched on Jan. 28, 2025, but could not reach its designated orbit due to a ...

Does Novartis (NVS) have what it takes to be a top stock pick for momentum investors? Let's find out.

Novartis raises 2025 sales and profit forecast as key drugs drive strong Q1 results; core operating income up 23% to $5.6 billion on higher net sales.